Clinical Trial Update: A Study to Evaluate the Safety and Efficacy of HL231 Solution for Inhalation in Patients With COPD [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial evaluating the safety and efficacy of HL231 inhalation solution in chronic obstructive pulmonary disease has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• HL231 (HL231)

Snippet

Sponsor: Haisco Pharmaceutical Group Co., Ltd. | Conditions: Chronic Obstructive Pulmonary Disease (COPD) | Phase 3 | Status: COMPLETED